NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
    • Research Themes Overview
    • Cancer
    • Cardiovascular Medicine
    • Digital Health from Hospital to Home
    • Gene and Cell Therapy
    • Genomic Medicine
    • Imaging
    • Inflammation across Tissues
    • Life-saving Vaccines
    • Metabolic Experimental Medicine
    • Modernising Medical Microbiology and Big Infection Diagnostics
    • Musculoskeletal
    • Preventive Neurology
    • Respiratory Medicine
    • Surgical Innovation, Technology and Evaluation
    • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > IBD treatments do not increase susceptibility to COVID-19, study finds

IBD treatments do not increase susceptibility to COVID-19, study finds

23 December 2020 · Listed under COVID-19, Inflammation across Tissues

Research by Oxford scientists has shown that rates of COVID-19 infection are not increased in patients with inflammatory bowel disease (IBD) who are being treated with the drugs infliximab or vedolizumab.

The study data suggest there is no reason for treatment with these drugs to be stopped.

The paper, published on the pre-print server medRxiv, was produced by researchers at the Oxford Translational Gastroenterology Unit and the Department of Laboratory Immunology, both based at Oxford University Hospitals NHS Foundation Trust. The study was supported by the NIHR Oxford Biomedical Research Centre.

The study was launched to address concerns amongst clinicians and patients that immunomodulatory treatments for IBD may increase the risk of susceptibility to SARS-CoV-2 or of progression to severe disease.

The blood from 640 patients attending the John Radcliffe Hospital in Oxford and the Royal London Hospital for maintenance infliximab or vedolizumab infusions between April and June 2020 was tested. Demographic and clinical data were collated from electronic patient records and research databases.

Seropositivity rates of 3.0% were found in the Oxford in the Oxford cohort, lower than that seen in non-patient facing health-care workers within the same hospital. Rates of 7.2% and 12.5% were found in the London adult IBD cohort and London paediatric IBD cohort respectively. The latter rate was comparable to a contemporary healthy cohort collected at the same hospital.

The paper concluded: “SARS-CoV-2 seropositivity rates are not elevated in patients with IBD receiving maintenance infliximab or vedolizumab infusions. There is no rationale based on these data for elective interruption of maintenance therapy, and we recommend continuation of maintenance therapy.”

The data did not address the efficacy of vaccination in these patients.

← Trial finds no benefit from azithromycin in hospitalised COVID-19 patients
Oxford COVID-19 vaccinations begin →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre